80 related articles for article (PubMed ID: 15876401)
1. Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.
Yewle JN; Puleo DA; Bachas LG
Bioconjug Chem; 2011 Dec; 22(12):2496-506. PubMed ID: 22073906
[TBL] [Abstract][Full Text] [Related]
2. Optimization of an Injectable, Resorbable, Bioactive Cement Able to Release the Anti-Osteoclastogenic Biomolecule ICOS-Fc for the Treatment of Osteoporotic Vertebral Compression Fractures.
Banche-Niclot F; Corvaglia I; Cavalera C; Boggio E; Gigliotti CL; Dianzani U; Tzagiollari A; Dunne N; Manca A; Fiorilli S; Vitale-Brovarone C
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671479
[TBL] [Abstract][Full Text] [Related]
3. Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview.
Desai SA; Manjappa A; Khulbe P
J Egypt Natl Canc Inst; 2021 Feb; 33(1):4. PubMed ID: 33555490
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate conjugation for bone specific drug targeting.
Farrell KB; Karpeisky A; Thamm DH; Zinnen S
Bone Rep; 2018 Dec; 9():47-60. PubMed ID: 29992180
[TBL] [Abstract][Full Text] [Related]
5. Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis.
He F; Chiou AE; Loh HC; Lynch M; Seo BR; Song YH; Lee MJ; Hoerth R; Bortel EL; Willie BM; Duda GN; Estroff LA; Masic A; Wagermaier W; Fratzl P; Fischbach C
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10542-10547. PubMed ID: 28923958
[TBL] [Abstract][Full Text] [Related]
6. Bone-seeking agents for the treatment of bone disorders.
Cawthray J; Wasan E; Wasan K
Drug Deliv Transl Res; 2017 Aug; 7(4):466-481. PubMed ID: 28589453
[TBL] [Abstract][Full Text] [Related]
7. Molecular Design of Bisphosphonate-Modified Proteins for Efficient Bone Targeting In Vivo.
Katsumi H; Sano J; Nishikawa M; Hanzawa K; Sakane T; Yamamoto A
PLoS One; 2015; 10(8):e0135966. PubMed ID: 26287482
[TBL] [Abstract][Full Text] [Related]
8. Modular 'click-in-emulsion' bone-targeted nanogels.
Heller DA; Levi Y; Pelet JM; Doloff JC; Wallas J; Pratt GW; Jiang S; Sahay G; Schroeder A; Schroeder JE; Chyan Y; Zurenko C; Querbes W; Manzano M; Kohane DS; Langer R; Anderson DG
Adv Mater; 2013 Mar; 25(10):1449-54. PubMed ID: 23280931
[TBL] [Abstract][Full Text] [Related]
9. Targeting polymer therapeutics to bone.
Low SA; Kopeček J
Adv Drug Deliv Rev; 2012 Sep; 64(12):1189-204. PubMed ID: 22316530
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.
Segal E; Pan H; Benayoun L; Kopečková P; Shaked Y; Kopeček J; Satchi-Fainaro R
Biomaterials; 2011 Jul; 32(19):4450-63. PubMed ID: 21429572
[TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics.
Segal E; Pan H; Ofek P; Udagawa T; Kopecková P; Kopecek J; Satchi-Fainaro R
PLoS One; 2009; 4(4):e5233. PubMed ID: 19381291
[TBL] [Abstract][Full Text] [Related]
12. Selective drug delivery to bone using acidic oligopeptides.
Ishizaki J; Waki Y; Takahashi-Nishioka T; Yokogawa K; Miyamoto K
J Bone Miner Metab; 2009; 27(1):1-8. PubMed ID: 19018455
[No Abstract] [Full Text] [Related]
13. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.
Pan H; Sima M; Kopecková P; Wu K; Gao S; Liu J; Wang D; Miller SC; Kopecek J
Mol Pharm; 2008; 5(4):548-58. PubMed ID: 18505266
[TBL] [Abstract][Full Text] [Related]
14. Designing proteins for bone targeting.
Gittens SA; Bansal G; Zernicke RF; Uludağ H
Adv Drug Deliv Rev; 2005 May; 57(7):1011-36. PubMed ID: 15876401
[TBL] [Abstract][Full Text] [Related]
15. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents.
Zhang S; Gangal G; Uludağ H
Chem Soc Rev; 2007 Mar; 36(3):507-31. PubMed ID: 17325789
[TBL] [Abstract][Full Text] [Related]
16. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro.
Hengst V; Oussoren C; Kissel T; Storm G
Int J Pharm; 2007 Mar; 331(2):224-7. PubMed ID: 17150316
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate conjugation to proteins as a means to impart bone affinity.
Uludag H; Kousinioris N; Gao T; Kantoci D
Biotechnol Prog; 2000; 16(2):258-67. PubMed ID: 10753453
[TBL] [Abstract][Full Text] [Related]
18. Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates.
Gittens SA; Bagnall K; Matyas JR; Löbenberg R; Uludag H
J Control Release; 2004 Aug; 98(2):255-68. PubMed ID: 15262417
[TBL] [Abstract][Full Text] [Related]
19. Bone-targeting macromolecular therapeutics.
Wang D; Miller SC; Kopecková P; Kopecek J
Adv Drug Deliv Rev; 2005 May; 57(7):1049-76. PubMed ID: 15876403
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
